AbbVie Inc. Annual Deferred Federal Income Tax Expense (Benefit) in USD from 2011 to 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
AbbVie Inc. annual Deferred Federal Income Tax Expense (Benefit) history and growth rate from 2011 to 2023.
- AbbVie Inc. annual Deferred Federal Income Tax Expense (Benefit) for 2023 was -$2.32B, a 53.7% decline from 2022.
- AbbVie Inc. annual Deferred Federal Income Tax Expense (Benefit) for 2022 was -$1.51B, a 80.2% decline from 2021.
- AbbVie Inc. annual Deferred Federal Income Tax Expense (Benefit) for 2021 was -$839M, a 1347% decline from 2020.
Deferred Federal Income Tax Expense (Benefit), Annual (USD)
Deferred Federal Income Tax Expense (Benefit), YoY Annual Growth (%)